翰森制药引入透析领域创新药 深化肾科领域布局

Core Viewpoint - Hansoh Pharmaceutical (3692.HK) has entered into a licensing agreement to obtain exclusive rights for the development, production, and commercialization of the innovative drug SHR6508 in China (excluding Hong Kong, Macau, and Taiwan) [1] Group 1: Product Development - SHR6508 is a calcium-sensing receptor (CaSR) allosteric modulator currently in Phase III clinical trials, intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) requiring dialysis [1] - This collaboration signifies Hansoh Pharmaceutical's further deepening of its product portfolio in the nephrology sector, enhancing its core competitiveness [1] Group 2: Market Position - Hansoh Pharmaceutical has already launched an innovative nephrology drug, Shengluo Lai® (Pemosaject), in 2023, which is used for treating renal anemia [1] - The company possesses a mature commercialization system and market access capabilities in the fields of nephrology and dialysis [1]